Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A novel small molecule RAD51 inactivator overcomes imatinib-resistance in chronic myeloid leukaemia.

EMBO molecular medicine - 1 Mar 2013

Zhu Jiewen, Zhou Longen, Wu Guikai, Konig Heiko, Lin Xiaoqin, Li Guideng, Qiu Xiao-Long, Chen Chi-Fen, Hu Chun-Mei, Goldblatt Erin, Bhatia Ravi, Chamberlin A Richard, Chen Phang-Lang, Lee Wen-Hwa

Abstract excerpt

RAD51 recombinase activity plays a critical role for cancer cell proliferation and survival, and often contributes to drug-resistance. Abnormally elevated RAD51 function and hyperactive homologous recombination (HR) rates have been found in a panel of cancers, including breast cancer and chronic myeloid leukaemia (CML). Directly targeting RAD51 and attenuating the deregulated RAD51 activity has therefore been...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Fusion Proteins, bcr-abl

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Homologous Recombination

Share to Imatinib Mesylate

Share to Mice, Inbred NOD

Share to Proteasome Inhibitors

Share to Rad51 Recombinase

Share to Tumor Burden

Source

Open in PubMed Open full text

Identifiers

PMID: 23341130
DOI: 10.1002/emmm.201201760
PMCID: PMC3598077

Genes

RAD51
BCR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A novel small molecule RAD51 inactivator overcomes imatinib-resistance in chronic myeloid leukaemia.PMID 23341130Read ↗

Regulation and pharmacological targeting of RAD51 in cancerSemantic proximity Read ↗

Targeting RAD51-Mediated Homologous Recombination as a Treatment for Advanced Solid and Hematologic Malignancies: Opportunities and Challenges AheadSemantic proximity Read ↗

A Small Molecule Inhibitor of Human RAD51 Potentiates Breast Cancer Cell Killing by Therapeutic Agents in Mouse XenograftsSemantic proximity Read ↗

RAD51 Is Implicated in DNA Damage, Chemoresistance and Immune Dysregulation in Solid TumorsSemantic proximity Read ↗

Systematic Screen Identifies miRNAs That Target RAD51 and RAD51D to Enhance ChemosensitivitySemantic proximity Read ↗

Cediranib suppresses homology-directed DNA repair through down-regulation of BRCA1/2 and RAD51Semantic proximity Read ↗

Targeting homologous recombination, new pre-clinical and clinical therapeutic combinations inhibiting RAD51Semantic proximity Read ↗

New RAD51 Inhibitors to Target Homologous Recombination in Human CellsSemantic proximity Read ↗

A Small-Molecule Inhibitor of RAD51 Reduces Homologous Recombination and Sensitizes Multiple Myeloma Cells to DoxorubicinSemantic proximity Read ↗

RAD51, genomic stability, and tumorigenesis.Semantic proximity Read ↗

RAD51 as a potential surrogate marker for DNA repair capacity in solid malignanciesSemantic proximity Read ↗

miR-506: a regulator of chemo-sensitivity through suppression of the RAD51-homologous recombination axisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.